Preview

Cancer Urology

Advanced search

Prognostic factors of the therapeutic efficacy of mTOR and VEGFR inhibitors in patients with metastatic renal cell carcinoma

https://doi.org/10.17650/1726-9776-2015-11-4-34-41

Abstract

Background. Thorough study of the molecular genetic alterations in patients with hereditary and sporadic renal cell carcinoma (RCC) enabled to reveal potential therapeutic targets - vascular endothelial growth factor (VEGF), platelet-derived growth factor (PDGF), growth factor receptors (VEGFR, PDGFR, EGFR, FGFR), mTOR signaling protein. Advances in targeted therapy treatment in the current therapeutic practice have brought a problem of its rational use and ultimately effective outcomes. The main solution of solving this problem is to establish independent clinical and laboratory prognostic factors and molecular markers which could predict the efficacy of targeted therapy.

Objective – optimization of targeted therapy in patients with RCC by using both molecular and genetic prognostic factors as predictors of the treatment efficacy.

Materials and methods. We assessed the level of mRNA expression of 13 potential target genes in primary tumor and metastatic site of patients suffering from metastatic RCC (n = 43) and evaluated the influence of the selected genes’ expression on the therapeutic efficacy of mTOR inhibitors and VEGFR inhibitors.

Conclusion. VEGFR1 mRNA overexpression in metastatic site as well as mTOR and/or PI3K mRNA overexpression could be assessed as potential biomarkers in predicting the treatment efficacy of VEGFR inhibitors and mTOR inhibitors respectively. The higher expression of RAF1 mRNA and mTOR signaling pathway are not typical molecular alterations in patients with mRCC. RAF1 mRNA overexpression in metastatic site as well as activation of the alternative signaling pathway (RAS-RAF-MAPK) in tumor cell are negative prognostic factors of the efficacy of targeted therapy. Activation of the signaling RAS-RAF-MAPK pathway in tumor cells is probably an alternative independent mechanism that “drives” tumor development in certain groups of patients.

About the Authors

Е. А. Voroshilova
N.N. Blokhin Russian Cancer Research Center of the Ministry of Health of Russia; 23 Kashirskoe Shosse, Moscow, 115478, Russia
Russian Federation


N. V. Apanovich
N.N. Blokhin Russian Cancer Research Center of the Ministry of Health of Russia; 23 Kashirskoe Shosse, Moscow, 115478, Russia
Russian Federation


D. A. Nosov
N.N. Blokhin Russian Cancer Research Center of the Ministry of Health of Russia; 23 Kashirskoe Shosse, Moscow, 115478, Russia
Russian Federation


А. V. Karpukhin
N.N. Blokhin Russian Cancer Research Center of the Ministry of Health of Russia; 23 Kashirskoe Shosse, Moscow, 115478, Russia
Russian Federation


I. N. Sokolova
N.N. Blokhin Russian Cancer Research Center of the Ministry of Health of Russia; 23 Kashirskoe Shosse, Moscow, 115478, Russia
Russian Federation


M. Yu. Fedyanin
N.N. Blokhin Russian Cancer Research Center of the Ministry of Health of Russia; 23 Kashirskoe Shosse, Moscow, 115478, Russia
Russian Federation


References

1. Статистика злокачественных новообразований в России и странах СНГ в 2012 г. Под ред. М.И. Давыдова, Е.М. Аксель. М.: Издательская группа РОНЦ. 2014. [Statistical data on malignant neoplasms in Russia and CIS countries in 2012. Ed. by M.I. Davydov, E.M. Axel. Moscow: of N.N. Blokhin RСRC. (In Russ.)].

2. Матвеев В.Б., Волкова М.И. Рак почки. Русский медицинский журнал 2007;14:1094–9. [Matveyev V.B., Volkova M.I. Renal cell carcinoma. Russkiy meditsinskiy zhournal = Russian Journal of medicine 2007;14:1094–9. (In Russ.)].

3. Motzer R.J., Bacik J., Schwartz L.H. et al. Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J Clin Oncol 2004;22:454–63.

4. Motzer R.J., Nosov D, Eisen T. et al. Tivozanib versus sorafenib as initial targeted therapy for patients with metastatic renal cell carcinoma: results from a phase III trial. J Clin Oncol 2013;31(30):3791–9.

5. Nosov D., Esteves B., Lipatov O.N. et al. Antitumor activity and safety of tivozanib (AV-951) in a phase II randomized discontinuation trial in patients with renal cell carcinoma. J Clin Oncol 2012;30:1678–85.

6. Pantuck A., Seligson D., Klatte T. et al. Prognostic relevance of the mTOR pathway in renal cell carcinoma: implications for molecular patient selection for targeted therapy. Cancer 2007;11:2257–67.

7. Rini B.I., Michaelson M.D., Rosenberg J.E. et al. Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab refractory metastasis renal cell carcinoma. J Clin Oncol 2008;26:3743–8.

8. Haddad A.Q., Kapur P., Singla N. et al. Validation of mammalian target of rapamycin biomarker panel in patients with clear cell renal cell carcinoma. Cancer 2015;121(1):43–50.

9. Li S., Kong Y., Si L. et al. Phosphorylation of mTOR and S6RP predicts the efficacy of everolimus in patients with metastatic renal cell carcinoma. BMC Cancer 2014;14:376. doi: 10.1186/1471-2407-14-376.

10. You D., Song S.H., Cho Y.M. et al. Predictive role of tissue-based molecular markers in patients treated with sunitinib for metastatic renal cell carcinoma. World J Urol 2015;33:111–8.

11. Motzer R.J., Hutson T.E., Hudes G.R. et al. Investigation of novel circulating proteins, germ line single-nucleotide polymorphisms, and molecular tumor markers as potential efficacy biomarkers of first-line sunitinib therapy for advanced renal cell carcinoma. Canc Chemother Pharmacol 2014;74: 739–50.

12. Dornbusch J., Zacharis A., Meinhardt M. et al. Analyses of potential predictive markers and survival data for a response to sunitinib in patients with metastatic renal cell carcinoma. PLoS One 2013;8:1–16.

13. Gerlinger M., Rowan A.J., Horswell S. et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 2012;10:883–92.

14. Nassar A., Radhakrishnan A., Cabrero I.A. et al. Intratumoral heterogeneity of immunohistochemical marker expression in breast carcinoma: a tissue microarray-based study. Appl Immunohistochem Mol Morphol 2010;18:433–41.

15. Fiorini C., Massari F., Pedron S. et al. Methods to identify molecular expression of mTOR pathway: a rational approach to stratify patients affected by clear cell renal cell carcinoma for more likely response to mTOR inhibitors. Am J Cancer Res 2014;4:907–15.


Review

For citations:


Voroshilova Е.А., Apanovich N.V., Nosov D.A., Karpukhin А.V., Sokolova I.N., Fedyanin M.Yu. Prognostic factors of the therapeutic efficacy of mTOR and VEGFR inhibitors in patients with metastatic renal cell carcinoma. Cancer Urology. 2015;11(4):34-41. (In Russ.) https://doi.org/10.17650/1726-9776-2015-11-4-34-41

Views: 1061


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 1726-9776 (Print)
ISSN 1996-1812 (Online)
X